APELLIS PHARMACEUTICALS INC's ticker is APLS and the CUSIP is 03753U106. A total of 46 filers reported holding APELLIS PHARMACEUTICALS INC in Q4 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $422,666,662 | -58.2% | 11,111,111 | 0.0% | 6.59% | -52.0% |
| Q2 2023 | $1,012,222,212 | +38.1% | 11,111,111 | 0.0% | 13.73% | +26.4% |
| Q1 2023 | $732,888,882 | +33.4% | 11,111,111 | +4.6% | 10.86% | +32.3% |
| Q4 2022 | $549,418,750 | -20.6% | 10,625,000 | +4.9% | 8.21% | -35.7% |
| Q3 2022 | $691,538,000 | +56.0% | 10,125,000 | +3.3% | 12.78% | +45.8% |
| Q2 2022 | $443,382,000 | -7.7% | 9,805,000 | +3.8% | 8.76% | -0.0% |
| Q1 2022 | $480,155,000 | +18.7% | 9,450,000 | +10.5% | 8.77% | +27.3% |
| Q4 2021 | $404,507,000 | +143.6% | 8,555,555 | +31.3% | 6.88% | +163.9% |
| Q3 2021 | $166,060,000 | +148.3% | 6,515,000 | +423.2% | 2.61% | +124.3% |
| Q2 2021 | $66,891,000 | +55.9% | 1,245,230 | +24.5% | 1.16% | +57.0% |
| Q1 2021 | $42,910,000 | +475.7% | 1,000,000 | +152.1% | 0.74% | +108.1% |
| Q1 2018 | $7,454,000 | +1.9% | 396,635 | 0.0% | 0.36% | -24.9% |
| Q4 2017 | $7,316,000 | – | 396,635 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 1,526,122 | $29,759,000 | 24.10% |
| Cormorant Asset Management, LP | 3,600,000 | $70,200,000 | 4.74% |
| SECTORAL ASSET MANAGEMENT INC | 1,727,829 | $33,693,000 | 4.05% |
| Hillhouse Capital Management | 2,098,581 | $40,922,000 | 1.71% |
| HHLR ADVISORS, LTD. | 2,579,708 | $50,304,000 | 1.40% |
| CLOUGH CAPITAL PARTNERS L P | 589,734 | $11,500,000 | 1.01% |
| Vivo Capital, LLC | 383,538 | $7,479,000 | 0.75% |
| Opaleye Management Inc. | 115,000 | $2,243,000 | 0.62% |
| Virtus ETF Advisers LLC | 14,338 | $280,000 | 0.60% |
| Eversept Partners, LP | 104,349 | $2,034,806 | 0.59% |